SK pharmteco Inc is pleased to announce that Joyce Fitzharris has been appointed General Manager, SK biotek Ireland.
SK pharmteco Inc is pleased to announce that Joyce Fitzharris has been appointed General Manager, SK biotek Ireland. Joyce has been leading Operations in Swords, Dublin, on an interim basis since December 2019.
“Joyce has led our Swords Campus through transition and integration into the successful business entity it is today. She is highly respected by all who work for and with her. I have no doubt SK’s Swords Campus will continue to flourish under Joyce’s leadership, and I am delighted to welcome Joyce formally to the SK pharmteco Executive Management Team”, said Dr. Aslam Malik, CEO of SK pharmteco, the parent company of SK biotek Ireland.
“I am delighted to be a part of the growing SK Pharmteco Global CDMO and know our Swords Campus will continue to play a key leadership role. Our Team is excited to play our part in the manufacture of critical APIs for our customers and their patients worldwide” shares Ms. Fitzharris.
Joyce has worked within the Active Pharmaceutical Ingredients (API) business for close to 30 years. She held multiple technical and Quality management positions with increasing levels of responsibility with Bristol Meyers Squibb (BMS) and managed Operational Excellence across several affiliated API sites while with BMS and later at SK biotek Ireland.
Joyce holds a B.Sc Analytical Science and a M.Sc Emergency Management from Dublin City University, and a M.Sc Environmental Protection from Sligo Regional Technical College, Ireland.
-ENDS-
ABOUT SK PHARMTECO & SK BIOTEK IRELAND
SK pharmteco is the single customer-facing team comprised of SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea. Creating substantial market synergies in the API CDMO space by combining highly complementary assets and expertise, this union enables us to provide the highest-quality services to our customers.
We feature state-of-the-art facilities and technology: energetic chemistry, continuous flow processes, simulated moving bed chromatography, controlled substances, particle engineering and commercial scale manufacturing of high potency APIs. We have multiple cGMP manufacturing and development sites, with ~1000m³ of capacity among 6 sites plus a dedicated analytical services facility, across USA, Korea and Ireland.
SK pharmteco is a portfolio company of SK holdings (South Korea) and serves as a strategic part of SK’s growing sector.
SK biotek Ireland, our facility in Dublin, known as Swords Campus, has been manufacturing API and Intermediates for over 55 years. For the last 30+ years, Swords Campus has maintained its leadership in the development, scale-up and commercial manufacture of highly potent chemical intermediates and APIs. SK biotek Ireland can today offer multi-scale plants from grams to 100s of kgs.
This integrated facility combines manufacturing plants, R&D and QC laboratories on the same site. Through the implementation of strong safety compliance policy and adherence to high-quality and safety standards, Swords Campus has a proven track record as a reliable supplier of APIs to multiple customers.
Additional information about SK biotek can be obtained by visiting our website at https://skbiotek.ie/
For clarification or further information contact:
Patrick Park, VP, Head of Global Business Development, SK pharmteco
Telephone: +1 (916) 357-6376 or email patrick.park@skpharmteco.com
Photos attached include: Joyce Fitzharris
